Evidence for different expression profiles for c-MET, EGFR, PTEN and the mTOR pathway in low and high grade endometrial carcinomas in a cohort of consecutive women. occurrence of PIK3CA and K-Ras mutations and microsatellite instability

Histology and Histopathology

Volumn 29, Issue 11, 2014, Pages 1455-1466

  Thoury, Anne ^a   Descatoire, Véronique ^a   Kotelevets, Larissa ^b   Kannengiesser, Caroline ^c   Bertrand, Guylène ^c   Theou Anton, Nathalie ^c   Frey, Caroline ^a   Genestie, Catherine ^a   Raymond, Eric ^d   Chastre, Eric ^b   Walker, Francine ^a,b  

^a Department of  Pathology ^*  (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c BICHAT HOSPITAL   (France)

^d BEAUJON HOSPITAL   (France)

Author keywords

C Met; EGFR; Endometrial cancer; mTOR pathway; PTEN

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KI 67 ANTIGEN; LIGAND; MICROSATELLITE DNA; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; CARCINOMA; ENDOMETRIUM TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; RETROSPECTIVE STUDY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LIGANDS; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOR SERINE-THREONINE KINASES;

EID: 84929904905     PISSN: 02133911     EISSN: 16995848     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ai Z., Wang J., Wang Y., Lu L, Tong J, and Tang Y. (2010). Overexpressed epidermal growth factor receptor (EGFR)-induced proges t in insensitivity in human endomet r ial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway. Cancer 116, 3603-3613.
2. Albitar l., Pickett G., Morgan M., Wilken J.A., Maihle N.J. and Leslie K.K. (2010). EGFR isoforms and gene regulation in human endometrial cancer cells. Mol. Cancer 9,166. 9, 156.
3. An H.J., Lee Y.H., Cho N.H., Shim J.Y., Kim J.Y., Lee C. and Kim S. J. (2002). Al terat ion of PTEN expres s ion in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 41, 437-445.
4. Bishop E.A., Lengyel E.R., Yamada S.D., Montag A. and Temkin S.M. (2011). The expression of hepatocyte growth factor and c-Met in uterine serous carcinoma. Gynecol. Oncol. 121, 218-223.
5. Catasus L., Gallardo A., Cuatrecasas M, and Prat J. (2009). Concomitant PIK3-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod. Pathol. 22, 522-529.
6. Choi C.H., Lee J.S., Kim T.J., Lee J.W., Kim B.G. and Bae D.S. (2010). Clinical significance of p-mTOR expression in endomet r ioid endomet rialcarc inoma. Eur. J. Obstet. Gynecol. Reprod. Biol. 153, 207-210.
7. Darb-Es fahani S., Faggad A., Nos ke A., Wei cher t W., Buchendahl A.C., Müller B., Budczies J., Röske A., Dietel M, and Denkert C. (2009). Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to Rapamycin treatment in vitro. J. Cancer Res. Clin. Oncol. 135, 933-941.
8. Darvishian F., Hummer A.J., Thaler H.T., Bhargava R., Linkov I., Asher M. and Soslow R.A. (2004). Serous endometrial cancer s that mimi c endomet r ial adenocar c inomas. A clinicopathologic and immunohistochemical study of a group of problematic cases. Am. J. Surg. Pathol. 28, 1568-1578.
9. Faivre S., Kroemer G, and Raymond E. (2006). Cur rent development of mTOR inhibitors as anticancer agents. Nat. Rev. 5, 671-688.
10. Gadducci A., Tana R., Cosio S., Fanucchi A. and Genazzani A.R. (2008). Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol. Endocrinol. 24, 239-249.
11. Garcia-Dios D.A., Lambrechts D., Coenegrachats L., Vandenput I., Capoen A., Webb P.M., Ferguson K., ANECS., Akslen L.A., Claes D., Vergote I., Moerman P., Van Robays J., Marcickiewicz J., Salvesen H.B., Spurdle A.B. and Amant F. (2013). High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol. Oncol. 128, 327-334.
12. Gilks C.B., Oliva E. and Soslow R.A. (2013). Poor intraobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. Am. J. Surg. Pathol. 37, 874-881.
13. Giordano S. (2009). Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer. Curr. Opin. Mol. Ther. 11,448-455.
14. Hayes M.P., Douglas W. and Ellenson L.H. (2009). Molecular al terat ions of EGFR and PIK3CA in uter ine serous carcinoma. Gynecol. Oncol.113, 370-373.
15. Kanamori Y., Kigawa J., Itamochi H., Sultana H., Suzuki M., Ohwada M., Kamura T., Sugiyama T., Kikuchi Y., Kita T., Fijiwara K. and Terakawa N. (2002). PTEN expression is associated with prognosis for patients with advanced endomet r ial car c inoma undergoing pos t operat i ve chemotherapy. Int. J. Cancer 100, 686-689.
16. Kang S., Seo S.S., Chang H.J., Yoo C.W., Park S.Y. and Dong S.M. (2008) Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma. Int. J. Gynecol. Cancer 18, 1339-1343.
17. Konecny G.E., Santos L., Winterhoff B., Hatmal M., Keeney G.L., Mariani A., Jones M., Neuper C., Thomas D., Muderspach L., Riehle D., Wang H.J., Dowdy S., Podratz K.C, and Press M.F. (2009). HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with non endometrioid (type 2) endometrial cancer. Br. J. Cancer 100, 89-95.
18. Konopka B., Janiec-Jankowska A., Kwiatkowska E., Najmota U., Bidzinski M., Olszewski W. and Goluda C. (2011). PIK3CA mutations and amplification in endometrioid endometrial car c inomas : relat ion to other genet i c defec t s and clinicopathologic status of the tumors. Hum. Pathol. 42, 1710-1719.
19. Kounelis S., Kapranos N., Kouri E., Coppola D., Papadaki H. and Jones M.W. (2000). Immunohistochemical profile of endometrial carcinoma: A study of 61 cases and review of the literature. Mod. Pathol. 13, 379-388.
20. Llaurado M., Ruiz A., Majem B., Ertekin T., Colas E., Pedrola N., Devis L., Rigau M., Sequeiros T., Montes M., Garcia M., Cabrera S., Gil-Moreno A., Xercavins J., Castellvi J., Garcia A., Ramony Cajal S., Moreno G., Alameda F., Vazquez-Levin M., Palacios J., Prat J., Doll A., Matias-Guiu X., Abal M. and Reventos J. (2012). Molecular bases of endometrial cancer: new roles for new actors in the diagnosis and the therapy of the disease. Mol. Cell. Endocrinol. 358, 244-255.
21. Lu K.H., Wu W., Dave B., Slomovitz B.M., Burke T.W., Munssel M.F., Broaddus R.R. and Walker C.L. (2008). Loss of tuberous sclerosis complex-2 function and activation of mammalian target of rapamycin signaling in endometrial carcinoma. Clin. Cancer Res. 14, 2543-2450
22. McConechy M.K., Ding J., Cheang M.C., Wiegand K.C., Senz J., Tone A.A., Yang W., Prentice L.M., Tse K., Zeng T., McDonald H., Schmidt A.P., Mutch D.G., McAlpine J.N., Hirst M., Shah S.P., Lee C.H., Goodfellow P.J., Gilks C.B. and Huntsman D.G. (2012). Use of mutation profile to refine the classification of endometrial carcinomas. J. Pathol. 228, 20-30.s
23. Matias-Guiu X. and Prat J. (2013). Molecular pathology of endometrial carcinoma. Histopathology 62, 111-123.
24. Matias-Guiu X., Catasus L., Bussaglia E., Lagarda H., Garcia A., Pons C., Muñoz J., Argüelles R., Machin P. and Prat J. (2001). Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol. 32, 569-577.
25. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S. and Bardelli A. (2005). Gene copy number for epidermal growth factor receptor and clinical response to anti-EGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6, 279-286.
26. Ng P.C. and Henikoff S. (2003). SIFT. Predicting amino acid changes that affect protein function. Nucleic Acids Res. 31, 3812-3814.
27. Oda K., Okada J., Timmerman L., Rodriguez-Viciana P., Stokoe D., Shoji K., Taketani Y., Kuramoto H., Knight Z.A., Shokat K.M. and McCormick F. (2008). PIK3CA cooperates with other phosphatidylinositol 3’-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 68, 8127-8136.
28. Okuda T., Sekizawa A., Purwosunu Y., Nagatsuka M., Morioka M., Hayashi M. and Okai T. (2010). Genetics of endometrial cancers. Obstet. Gynecol. Int. 2010, 984013.
29. Oza A.M., Eisenhauer E.A., Elit L., Cutz J.C., Sakurada A., Tsao M.S., Hoskins P.J., Biagi J., Ghatage P., Mazurka J., Provencher D., Dore N., Dancey J. and Fyles A. (2008). Phase I I study of er lot inib in recur rent or metastatic endometrial cancer. J. Clin. Oncol. 10, 4319-4325.
30. Peterson L.M., Kipp B.R., Halling K.C., Kerr S.E., Smith D.I., Distad T.J., Clayton A.C. and Medeiros F. (2012). Molecular Characterization of endometrial cancer: correlative study assessing microsatellite instability, MLH1 hypermethylation, DNA mi smat ch repai r protein expres s ion, and PTEN, PIK3CA, KRAS, and BRAF mutat ion analysis. Int. J. Gynecol. Pathol. 31, 195-205.
31. Rowlands I.J., Nagle C.M., Spurdle A.B., Webb P.M. and Australian National Endometrial Cancer Study Group and Aus t ral ian Ovar ian Cancer Study Group. (2011). Gynecological conditions and the risk of endometrial cancer. Gynecol. Oncol. 123, 537-541.
32. Ruvinsky I. and Meyuhas O. (2006). Ribosomal protein S6 phosphorylation: from protein synthesis to cell size. Trends Biochem. Sci. 31, 342-348.
33. Samarnthai N., Hall K. and Yeh I-T. (2010). Molecular profiling of endometrial malignancies. Obstet. Gynecol. Int. 2010, 162363.
34. Silverberg S.G., Kurman R.J., Nogales F., Mutter G.L., Kubik-Huch R.A. and Tavassoli F.A. (2003). Tumours of the uterine corpus. In: World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the breast and female genital organs. (Chapter 4). Tavassoli F.A. and Devilee P. (eds). IARC Press, Lyon. pp. 221-232.
35. Soslow R.A. (2013). High-Grade endometrial carcinomas –strategies for typing. Histopathology 62, 89-110.
36. Spiegel D.R., Edelman M.J., Mok T., O’Byrne K., Paz-Ares L., Yu W., Rittweger K. and Thurm H. (2012). Treatment rationale study design for thje Metlung trial: A randomized, double-blind phase III study of Onartuzumab (MetMab) in combination with Erlotinib versus Erlotinib alone in patients who have received standard chemotherapy for stage IIIB or IV Met-positive non-small-cell lung cancer. Clin. Lung Cancer 13, 500-504.
37. Stefansson I., Akslen L.A., MacDonald N., Ryan A., Das S., Jacobs I.J. and Salvesen H.B. (2002). Loss of hMSH2 and hMSH6 expression is frequent in sporadic endometrial carcinomas with microsatellite ins tability: a population-based study. Clin. Cancer Res. 8, 138-143.
38. Uegaki K., Kanamori Y., Kigawa J., Kawaguchi W., Kaneko R., Naniwa J., Takahashi M., Shimada M., Oishi T., Itamochi H. and Terakawa N. (2005). PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncol. Rep. 14, 389-392.
39. Velasco A., Bussaglia E., Pallares J., Dolcet X., Llobet D., Encinas M., Llecha N., Palacios J., Prat J. and Matias-Guiu X. (2006). PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum. Pathol. 37,1465-1472.
40. Voss M.A., Ganesan R., Ludeman L., McCarthy K., Gornall R., Schaller G., Wei W. and Sundar S. (2012). Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer -a clinical and pathological evaluation. Gynecol. Oncol. 124, 15-20.
41. Wagatsuma S., Konno R., Sato S. and Yajima A. (1998). Tumor angiogenesis, hepatoc y te growth fac tor, and c –Met expression in endometrial carcinoma. Cancer 82, 520-530.
42. Walker F., Kermorgant S., Darai E., Madelenat P., Cremieux A.C., Hénin D. and Lehy T. (2003). Hepatocyte growth factor and c -Metincervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodefiociency virus. Clin. Cancer Res. 9, 273-284.
43. Walker F., Abramowitz L., Benabderrahmane D., Duval X., Descatoire V., Hénin D., Lehy T. and Aparicio T. (2009). Growth factor receptor expression in anal squamous lesions: modifications associated with oncogenic human papillomavirus and human immunodeficiency virus. Hum. Pathol. 40, 1517-1527.
44. Wong Y.F., Cheung T.H., Lo K.W., Yim S.F., Chan L.K., Buhard O., Duval A., Chung T.K. and Hamelin R. (2006). Detection of microsatellite instability in endometrial cancer: advantages of a panel of five mononucleotide repeats over the National Cancer Institute panel of markers. Carcinogenesis 27, 951-955.
45. Zhu C., Luo J., Shi H., Xie X. and Ding Z. (2009). Expression of tubulin, p53, Ki67, receptors for estrogen and progesterone in endometrial cancer. Eur. J. Gynaecol. Oncol. 30, 514-517.